ImmunoTherapyNews.net

Cancer immunotherapy

Xagena Mappa
Medical Meeting
XagenaNewsletter
Neurobase.it

Nivolumab ( Opdivo ) is a programmed death-1 ( PD-1 ) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in patients with melano ...


PD-1 antibody, Nivolumab ( Opdivo ), was administered with/without a multi-peptide vaccine to 126 patients ( pts ) with unresectable melanoma that failed at least one regimen and were Ipilimumab ( Yer ...


Programmed death-1 ( PD-1 ) is a co-inhibitory receptor expressed on activated T cells which regulates antitumor immunity. Nivolumab ( Opdivo ) is a fully-humanized IgG4 that blocks the engagement o ...


Uveal melanomas are a rare type of melanoma with only 5-7 cases per 1 million persons diagnosed each year. Patients with metastatic melanoma of uveal origin, tend to have lower response rates on tradi ...


The results of the pivotal OPTiM study have shown that Talimogene laherparepvec monotherapy is the first oncolytic immunotherapy to demonstrate therapeutic benefit in a phase 3 trial for patients with ...


Both Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody ( Yervoy ) and Nivolumab, an anti–programmed death 1 monoclonal antibody ( Opdivo ), have been approved by the ...


Adoptive cell therapy ( ACT ) for cancers using autologous tumor-infiltrating lymphocytes ( TILs ) can induce immune responses and antitumor activity in metastatic melanoma patients. Researchers a ...


Programmed cell death ligand-1 ( PD-L1 ) is widely expressed on antigen presenting cells ( APC ) and other immune cells. PD-L1 binds two important regulatory receptors on T-cells: programmed cell deat ...


Although tumor infiltrating lymphocyte ( TIL ) density is prognostic and predictive in colorectal cancer ( CRC ), the impact of tumor genetics upon colorectal immunobiology is unclear. Identification ...


A phase 1/2 clinical trial evaluating dosing, safety, immunogenicity, and overall survival on metastatic colorectal cancer ( mCRC ) patients after immunotherapy with an advanced-generation Ad5 [E1-, E ...


Clinical outcome of patients with metastatic prostate cancer ( mPC ) at diagnosis is heterogeneous and unpredictable; thus alternative treatments such as immunotherapy are investigated. Researcher ...


Nivolumab ( Opdivo ) was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with Ipilimumab-refractory metastatic melanoma. The use of Nivolum ...


The anti-programmed death-1 ( PD-1 ) antibody Nivolumab ( Opdivo ) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected ...


Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. Researchers have assessed the activity of Nivolumab ( Opdivo ), a fully human IgG4 PD-1 ...


Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation of PD-L1 and inhibition of antitumor T-cell activation is obs ...